Summary SARA, an early endosomal protein, plays a key role in TGFb signalling, as it presents SMAD2 and SMAD3 for phosphorylation by the activated TGFb receptors. Here, we show that ERBIN is a new SARA-interacting protein that can be recruited by SARA to early endosomes. ERBIN was recently shown to bind and segregate phosphorylated SMAD2 and SMAD3 (SMAD2/3) in the cytoplasm, thereby inhibiting SMAD2/3-dependent transcription. SARA binds to ERBIN using a new domain, which we have called the ERBID (ERBIN-binding domain), whereas ERBIN binds to SARA using a domain (amino acids 1208-1265) that also interacts with SMAD2 and SMAD3, which we have called the SSID (SARA-and SMAD-interacting domain). We additionally show that SARA competes with SMAD2/3 for binding to ERBIN. In agreement, overexpression of SARA or the ERBID peptide reverses the inhibitory effect of ERBIN on SMAD2/3-dependent transcription. Taken together, these data suggest that the response of cells to TGFb and activin A can be influenced by the relative concentrations of SARA, ERBIN and SMAD2/3.
Introduction
The transforming growth factor b (TGFb) family of ligands consists of evolutionarily conserved pleiotropic secreted cytokines, which include TGFb1, activins and bone morphogenetic proteins (BMPs). Individual members of this family play crucial roles in multiple processes throughout development and in the maintenance of tissue homeostasis in adult life (Massague and Gomis, 2006; Feng and Derynck, 2005) . As a consequence, deranged signalling by TGFb family members has been implicated in many human diseases, including cancer, fibrosis, and autoimmune and vascular diseases (ten Dijke and Arthur, 2007; Gordon and Blobe, 2008) . TGFb ligands trigger heteromeric complex formation between specific transmembrane type I and type II Ser/Thr kinase receptors, in which the type II receptor transphosphorylates and activates the type I receptor. Receptor SMADs (R-SMADs) are phosphorylated by type I receptors, and in turn can form heteromeric complexes with SMAD4. These activated SMAD complexes accumulate in the nucleus, where they directly or indirectly bind to specific promoter regions on target genes together with transcription factor and/or coactivators and co-repressors (Massague and Gomis, 2006) . SMAD anchor for receptor activation (SARA) was originally identified as a protein that functions to recruit non-phosphorylated SMAD2 and/or SMAD3 (SMAD2/3) to the activated receptors for phosphorylation by controlling their localisation. Indeed, SARA binds SMAD2/3 proteins through a specific domain called the SMAD-binding domain (SBD) . Receptor-induced phosphorylation of SMADs causes their dissociation from SARA and formation of SMAD2/3-SMAD4 complexes, which subsequently translocate to the nucleus to initiate signalling (Tsukazaki et al., 1998) . Although SARA is present at the plasma membrane, where it has been found to interact with TGFb receptors (Di Guglielmo et al., 2003) , it is mainly enriched on the early endosomal membrane through interactions mediated by its FYVE domain . The predominant localisation of SARA on early endosomes raises the question of whether phosphorylation of SMAD2/3 occurs at the plasma membrane or whether endocytosis to early endosomes is a prerequisite. Several reports, using a number of approaches, have clearly shown that trafficking of the TGFb receptor into the endocytic compartment enables TGFb signalling (Hayes et al., 2002; Penheiter et al., 2002) . Indeed, the current view is that TGFb receptors localise to both raft and non-raft membrane domains, and that the internalisation route dictates whether signalling or degradation will ensue. Internalisation of TGFb receptors, through the clathrin-coated pathway into EEA1-and SARA-positive endosomes, promotes signalling. However, internalisation through the raft-caveolar pathway, where SMAD7 and SMURF2 are localised, promotes ubiquitin-dependent receptor degradation. Indeed, inhibition of this pathway leads to receptor stabilisation, suggesting that trafficking of receptors to the SARA-positive early endosomes functions to sequester receptors from the rafts and caveolae, thereby stabilising the receptors (Di Guglielmo et al., 2003; Felberbaum-Corti et al., 2003) . Thus, partitioning between these two internalisation pathways appears to be a dynamic and balanced process influencing the signalling outcome of the activated TGFb family receptors (Di Guglielmo et al., 2003) .
SARA not only presents SMADs to the ligand-receptor complex for phosphorylation, but also recruits protein phosphatase 1 (PP1) to a specific domain downstream (i.e. further towards the C-terminal) of the SBD, thereby mediating TGFb receptor dephosphorylation (Bennett and Alphey, 2002) . Because SARA appears to play multiple roles in TGFb and activin A signalling, and particularly because of its endosomal localisation, we have undertaken the task of identifying SARAinteracting proteins with the aim of identifying additional endosomal proteins that participate in TGFb signalling. Among several interacting proteins, we have focused on the protein ERBIN, a protein that interacts with ERBB2 (also known as HER2) and is involved in the localisation and signalling of ERBB2 in epithelia (Borg et al., 2000) . Importantly, ERBIN has previously been shown to interact with SMAD proteins (Warner et al., 2003; Dai et al., 2007) . Here, we dissect the domains of SARA and ERBIN responsible for their interaction, we define ERBIN as a protein that can be recruited to the early endocytic compartment by SARA and we address the functional consequences of the ERBIN-SARA interaction in TGFb and activin A signalling.
Results

SARA interacts with ERBIN and recruits it to the early endocytic compartment
To identify SARA-interacting proteins, we carried out a yeast two-hybrid (Y2H) screen using the C-terminal region of SARA (SARAD1-664) as bait. Interestingly, besides known SARAinteracting proteins, such as the R-SMADs SMAD2 and SMAD3 (Tsukazaki et al., 1998) and PP1 (Bennett and Alphey, 2002) , the screen identified ERBIN as a putative new SARA-interacting protein. Four yeast two-hybrid clones were identified, mapping to a region of ERBIN between amino acids 1081 and 1265, which we designated as the Y2H interaction domain (Y2HID).
To validate the results of the Y2H screen, we carried out GSTpulldown experiments using GST-Y2HID and cell lysates from HEK-293 cells infected with adenoviruses expressing FLAG-SARA or FLAG-SARAD1-664. Indeed, the ERBIN Y2HID strongly interacted with both SARA and SARAD1-664 and not with control GST (Fig. 1A) . Likewise, Myc-ERBIN was coimmunoprecipitated with FLAG-SARAD1-664 in HEK-293 cell lysates, both in the presence and in the absence of TGFb1 (Fig. 1B) . Moreover, we generated a polyclonal antibody to ERBIN and could co-immunoprecipitate endogenous ERBIN and SARA (Fig. 1C) . In addition, immunoprecipitation of SARA pulled down endogenous ERBIN (Fig. 1C) . Therefore, we conclude that ERBIN is an interaction partner of SARA.
SARA interacts strongly with the membrane lipid PtdIns(3)-P, through its FYVE domain, being thus targeted to early endosomes Itoh et al., 2002) . Indeed, when placental membranes were floated over a sucrose gradient (Papanikolaou et al., 2005) , a small fraction of ERBIN was present in the same membrane fractions as SARA (Fig. 1D) . HEK-293 cell lysates expressing either FLAG-SARA or FLAG-SARAD1-664 were incubated with GST-ERBIN Y2HID or GST alone. The complexes were washed, analysed by SDS-PAGE and immunoblotted (IB) with an anti-FLAG antibody. (B) SARA and ERBIN interact as judged by co-immunoprecipitation of overexpressed proteins. HEK-293 cells were transiently transfected with Myc-ERBIN and infected with FLAG-SARAD1-664. Cell lysates were subjected to anti-FLAG immunoprecipitation (IP) and immunoblotted with an antiMyc antibody. The membranes were re-incubated with an anti-FLAG antibody to confirm the immunoprecipitation of FLAG-SARAD1-664. (C) Endogenous SARA and ERBIN interact as judged by co-immunoprecipitation. Upper panel: HEK-293 cell lysates were incubated with an anti-ERBIN antibody (a-ERBIN) or pre-immune serum, complexes were washed and analysed by immunoblotting using an anti-SARA antibody. The membranes were re-incubated with an anti-ERBIN antibody to confirm the immunoprecipitation of ERBIN. Lower panel: lysates from HCC-78 cells were incubated with an anti-SARA or anti-rabbit-IgG antibody. 10% of the complexes were probed with an anti-SARA antibody, whereas 90% were probed with an anti-ERBIN antibody. (D) Placental homogenate was fractionated using sucrose-gradient flotation followed by western blot analysis. Membranes were probed as indicated. EE indicates early-endosome-enriched fractions. Fractions are labelled 1-10 where 10 represents the bottom of the tube. I, input.
However, despite its association with SARA, as shown above, ERBIN has not been previously demonstrated to exhibit early endosomal localisation. Thus, we tested the colocalisation of overexpressed untagged ERBIN with the early endosomal marker EEA1 (Mu et al., 1995; Simonsen et al., 1998) . In agreement with previous reports (Borg et al., 2000) , ERBIN was found both at the plasma membrane and in the cytoplasm, exhibiting no colocalisation with EEA1 ( Fig. 2A-C) . However, upon coexpression of GFP-SARA, ERBIN exhibited considerable colocalisation (in ,50% of the cells) with GFP-SARA on early endosomes (Fig. 2D-F) . Overexpression of SARA caused enlargement of early endosomes, as shown previously (Fig. 2D-G) (Hu et al., 2002) . Apparently, the quantity of ERBIN recruited to early endosomes by endogenous levels of SARA is insufficient to be detected by the antibody used, although the flotation experiment showed that some ERBIN was present in the same membrane fractions as SARA (Fig. 1D) . Evidently, overexpression of GFP-SARA enriches this protein on early endosomes, thereby allowing detection of its interacting partner ERBIN. To characterise the domain of SARA responsible for the interaction with ERBIN, we investigated, in lysates of HEK-293 cells, the interaction of ERBIN Y2HID fused to GST with several HA-tagged constructs spanning the bait sequence of SARA (amino acids 664-1323) used in the Y2H screen (Fig. 3A) . GST-Y2HID interacted with SARA-1 (amino acids 667-926), but not with SARA-2 (amino acids 906-1204) or SARA-3 (amino acids 1170-1323) constructs (Fig. 3B ). As SARA-1 contains the SBD and PP1-phosphatase-binding motif (PP1BM), we investigated the involvement of these known domains of SARA in the interaction with ERBIN. We did not detect any binding of Myc-ERBIN to the SARA SBD, whereas, as a control, SMAD2 bound strongly to this GST-fusion protein (Fig. 3C) . As SARA-1DSBD and SARA-1DSBD-PP1BM interacted with GST-Y2HID of ERBIN (Fig. 3D) , we conclude that neither the SBD nor the PP1BM of SARA participate in the interaction of SARA with ERBIN. Therefore, it appears that SARA binds to ERBIN through a region between amino acids 730 and 926. We named this domain the ERBID (ERBIN-binding domain). To narrow down further the SARA area that interacts with ERBIN, we utilised a SARA N-terminal construct extending from amino acids 1 to 753 (Fig. 3E) . Indeed, this construct interacted with GST-Y2HID, suggesting that the region of SARA that interacts with ERBIN extends from amino acids 730 to 753. However, amino acids 730 to 760 of SARA interacted with ERBIN in a considerably weaker manner compared with that of amino acids 730-926 (Fig. 3F) , suggesting that additional amino acids are required for strong SARA-ERBIN interaction.
A new domain of ERBIN (amino acids 1208-1265) interacts with SARA, SMAD2 and SMAD3
To define more accurately the region of ERBIN that mediates binding to SARA, we tested the interaction of GST-Y2HID deletion mutants ( Fig. 4A ) with FLAG-SARAD1-664 using GST-pulldown assays in lysates of HEK-293 cells (Fig. 4B) . Initially, we used three overlapping regions of the ERBIN Y2HID, which we named E1 (amino acids 1081-1188), E2 (amino acids 1124-1215) and E3 (amino acids 1159-1265), and a fourth construct E4 (amino acids 1240-1371) containing the last 25 amino acids of the Y2HID followed by the PDZ domain (Fig. 4A) . As the Y2HID domain (amino acids 1081-1265) of ERBIN includes the SMAD-interacting domain (SID, amino acids 1172-1282) that has been previously shown to interact with SMAD2 and SMAD3 proteins (Dai et al., 2007) , we extended the GST-pulldown assays by also using FLAG-SMAD2, FLAG-SMAD3, Myc-SMAD1 and Myc-SMAD4 constructs ( Fig. 4C-F) . The ERBIN E3 and E4 GST-fusion constructs interacted strongly with SARAD1-664 ( Fig. 4B ) and SMAD2 (Fig. 4C) , whereas SMAD3 interacted predominantly with the E3 construct (Fig. 4D ). SMAD1 interacted mainly with the E3 construct, albeit in a much weaker manner (Fig. 4F ). SMAD4 interacted weakly and exclusively with the E1 construct (Fig. 4E) . Overall, these data demonstrate that SARA, SMAD2 and SMAD3 interact with the same area of ERBIN, extending from amino acids 1208 to 1265.
To define further the minimal region crucial for the interactions of SARA, SMAD2 and SMAD3 with ERBIN, we generated three additional ERBIN constructs, E3C (amino acids 1208-1265), E3C.1 (amino acids 1208-1240) and E3C.2 (amino acids 1241-1265) (Fig. 4A) . Whereas SARA and SMAD2 interacted only with E3C.2 (Fig. 4G,H ), SMAD3 interacted with both E3C.1 and E3C.2 (Fig. 4I) . As expected SARA, SMAD2 and SMAD3 interacted with the larger E3C construct (Fig. 4G-I ). By confirmation, SARA, SMAD2 and SMAD3 interacted with the E4 construct (Fig. 4J) , whereas none of the constructs interacted with E5 (Fig. 4J) , which is derived from E4 by deletion of amino acids 1240-1262 (Fig. 4A) . Thus, SARA and SMAD2 interact with ERBIN between amino acids 1241 and 1265, whereas SMAD3 binds ERBIN between amino acids 1208 and 1265. Collectively, these data establish a new binding domain in ERBIN (amino acids 1208-1265), which is responsible for the interaction with the SARA, SMAD2 and SMAD3 proteins. We have named this domain SSID (SARA-and SMAD-interacting domain).
Given that the same short region of ERBIN is responsible for its interaction with SARA, SMAD2 and SMAD3, we analysed in more detail the SSID and the Y2HID sequences. The SSID sequence is unusually rich in disorder-promoting residues, especially Pro and Gln, and poor in order-promoting amino acid residues (Trp, IIe, Cys and Val) (Fig. 4K) . Indeed, several relevant programs (see Materials and Methods) gave a convincing prediction of disorder for SSID, with the short segment comprising amino acids 1246-1257, expected to be ahelical, representing a 'dip' in the disorder prediction (Fig. 4K) . Moreover, the 1246-1257 segment could be classified as an aMoRF (for molecular recognition feature, also known as a molecular recognition element, MoRE). MoRFs are short, loosely structured protein regions embedded within longer largely disordered sequences, which, upon binding to their partner(s), undergo disorder-to-order transitions (Cheng et al., 2007) .
SMAD2/3 and SARA interact with ERBIN independently of each other, thereby competing with each other for binding to the SSID of ERBIN As SARA binds to ERBIN using a distinct domain from the SBD (i.e. the ERBID, SARA 730-926, Fig. 3 ) and the interaction was detected using the Y2H system, SARA and ERBIN must bind to each other directly. However, indirect interaction of ERBIN with SMAD2/3, through mutual binding to SARA, is also possible. To address this, we investigated whether ERBIN could interact with the phosphorylated SMAD2/3 proteins, which do not bind SARA (Tsukazaki et al., 1998) . To this end, we tested the interaction by examining co-immunoprecipitation of HA-ERBIN with Myctagged versions of either full-length SMAD2/3 or the constitutively active (ca) SMAD2 and SMAD3, in which the SSMS motif is mutated to EDME and EDVE, respectively, thereby mimicking the phosphorylated molecules . Both the non-phosphorylated and the constitutively active forms of SMAD2 and SMAD3 bound ERBIN to a similar extent ( Fig. 5A ) suggesting that binding of SMAD2/3 to ERBIN is independent of their binding to SARA. Consequently, given the fact that, first, SMAD2/3 and SARA can bind independently of each other to ERBIN and, second, SMAD2/3 and SARA bind to the SSID of ERBIN, we hypothesised that the interaction of SMAD2/3 and SARA to ERBIN could be competitive and mutually exclusive. Indeed, expression of increasing amounts of FLAG-SARA dramatically decreased the amount of MycSMAD2ca (Fig. 5C ) or Myc-SMAD3ca (Fig. 5B ) pulled down by the EC3 construct of ERBIN (the SSID, amino acids 1208-1265). Thus, SMAD2/3 and SARA interact with ERBIN independently of each other, thereby competing with each other for binding to the SSID of ERBIN.
SARA or its ERBID peptide attenuates the inhibitory effect of ERBIN on TGFb and activin A transcriptional responses
Because ERBIN binds both SARA and SMAD2/3, we investigated its role in TGFb and activin A signalling using a loss-of-function approach. To this end, we made two A431 stable cell lines in which the CAGA-luc SBE (SMAD-binding element) (responsive to TGFb and activin A) and the Renilla luciferase gene (constitutively expressed to correct the CAGA-luc values) were stably integrated. Using two different small interfering RNAs (siRNAs) for ERBIN, we were able to decrease the levels of endogenous ERBIN protein in stably transfected A431 cell lines compared with that in control cells as judged by western blot analysis (Fig. 6A) . Using both siRNAs in transcriptional response assays, we observed a significant increase of both activin-A-and TGFb-induced CAGA-luc levels (Fig. 6A) . Collectively, these results show that ERBIN plays an inhibitory role in TGFb and activin A transcriptional responses.
To verify the effect of ERBIN on TGFb and activin A signalling, we used a gain-of-function approach. For this purpose, we overexpressed ERBIN in HEK-293 cells co-transfected with each of the following three reporter constructs: (1) the CAGA-luc reporter, responsive to TGFb and activin A through SMAD3, (2) the ARE-luc (luciferase driven by the activin response element), responsive to activin A signalling through SMAD2 and cooperation with the transcription factor FAST, and (3) the BREluc (luciferase driven by the BMP response element) activated by BMPs through SMAD1 and/or SMAD5. As can be seen in Fig. 6B , overexpression of ERBIN strongly inhibited transcription of the CAGA-luc and ARE-luc reporters and also, to a lesser extent, BRE-luc transcription, whereas it exerted no effect on a SMADindependent promoter (E-selectin) (Fig. 6B) . The effect of ERBIN on the SBE-luc reporter was dose dependent (data not shown). Thus, ERBIN inhibits TGFb and activin A transcriptional activation and additionally has a negative effect on BMPinduced transcription, probably through its weak interaction with SMAD1 (Fig. 4F) . Importantly, overexpression of SARA and ERBID (SARA amino acids 730-926) or even the minimal interacting area (SARA amino acids 730-773) reverses the negative effect of ERBIN overexpression on the TGFb-induced transcriptional activation of CAGA-luc in a statistically significant manner (Fig. 6C,D) . Moreover, overexpression of the ERBID or SARA amino acids 730-773 enhances the transcriptional activity of TGFb, even in the absence of ERBIN overexpression (Fig. 6D) , apparently competing with endogenous ERBIN. By contrast, overexpression of SSID is sufficient to inhibit TGFb-induced transcription, whereas overexpression of isoform 7 of ERBIN (lacking the SSID) has no effect on transcriptional activation by TGFb (Fig. 7A) . These results indicate that competition of the ERBID (SARA) and the SSID (ERBIN) for binding to SMAD2/3 plays an important role in the response of cells to TGFb action.
As ERBIN binds both unphosphorylated and phosphorylated SMAD2/3 (Fig. 5A) , the ERBIN-unphosphorylated-SMAD complex could represent a pool of SMAD2/3 that is unavailable for binding to the SBD of SARA, thereby escaping presentation to the TGFb and activin receptors and subsequent phosphorylation. We tested this possibility by either saturating the SSID of ERBIN by overexpressing the ERBID or by silencing the ERBIN gene using siRNA. We did not find any effect on TGFb-induced phosphorylation of SMAD2/3 in either case (Fig. 7B) . Thus, the observed reversal of the inhibitory effect of ERBIN on TGFb-induced transcription upon overexpression of the ERBID (Fig. 6D ) must be a consequence of competition by SMAD2/3-P binding to the SSID of ERBIN. In support of this, whereas ERBIN decreased SMAD4-P-SMAD3 complex formation and inhibited SMAD2 nuclear accumulation, as expected (Fig. 7C,D) , coexpression of ERBID (SARA 730-926) led to increased SMAD4-P-SMAD3 complex formation ( Fig. 7C ) and nuclear accumulation of SMAD2 (Fig. 7D) . Thus, competition between SARA and ERBIN for binding to SMAD2/ 3-P has important consequences on the regulation of the TGFb and activin A functions in cells. Indeed, both silencing of the ERBIN gene and overexpression of the ERBID (SARA 730-926) exerted a positive effect on TGFb-dependent induction of plasminogen activator inhibitor 1 (PAI-1) expression (Fig. 7E) , whereas overexpression of the ERBID enhanced the inhibitory effect of TGFb on HaCaT cell proliferation (Fig. 7F ).
Discussion
In a Y2H screen for SARA-interacting proteins, among other proteins, we identified ERBIN, a member of the LAP family [containing LRR (leucine-rich repeat) and PDZ domains] (Borg et al., 2000) . LAP family members contain 16 LRRs at their Ntermini and up to four PDZ domains at their C-termini. The LAP family is composed of LET-413 in C. elegans, Scribble in Drosophila melanogaster, and ERBIN, densin-180 (also known as LRRC7), scribble and Lano (also known as LRRC1) in mammals, proteins that are considered to be adaptor proteins involved in polarity and/or receptor targeting (reviewed by Bryant and Huwe, 2000) . Indeed, ERBIN is a basolaterally localised LAP protein and has been shown to interact, through its PDZ domain, with ERBB2 of the epidermal growth factor receptor (EGFR) family, thereby restricting ERBB2 to the basolateral membrane of polarised epithelial cells (Borg et al., 2000) . Moreover, ERBIN interacts, through its LRR domain, with the scaffold protein Sur-8 disrupting the Sur-8-Ras-Raf complex, thereby inhibiting activation of extracellular signalregulated kinase 1 or 2 (ERK1/2) (Dai et al., 2006; Huang et al., 2003) . ERBIN also plays a crucial role in myelination, given that it binds to and stabilises ERBB2 receptor, which is necessary for NRG1 signalling (Tao et al., 2009 ). expressing Myc-SMAD3ca was incubated with GST-E3C, complexes were washed and increasing amounts of FLAG-SARA were added for competition. The complexes were washed, analysed by SDS-PAGE and immunoblotted with an anti-FLAG antibody to detect FLAG-SARA, and an anti-Myc antibody to detect Myc-SMAD3ca. The experiment was repeated, as in B, using Myc-SMAD2ca.
ERBIN has been implicated in TGFb signalling through its interaction with both non-phosphorylated and phosphorylated SMAD2/3 (Warner et al., 2003; Dai et al., 2007) . ERBIN overexpression inhibited TGFb-dependent transcription, whereas siRNA against ERBIN stimulated ligand-induced responses. ERBIN overexpression had no effect on ligand-induced phosphorylation of SMAD2/3; however, accumulation of SMAD2 in the nucleus was decreased. Therefore, a sequestering role for ERBIN was proposed, according to which ERBIN binds to phosphorylated SMAD2/3 preventing their association with SMAD4 and subsequent accumulation in the nucleus, thereby inhibiting TGFb signalling (Dai et al., 2007) . In agreement, we report that overexpression of ERBIN inhibits, whereas siRNA silencing of ERBIN enhances, TGFb-and activin-A-dependent transcription. However, we additionally demonstrate that ERBIN interacts also with SARA, another regulator of the TGFb and activin A pathway. Indeed, the initial Y2H interaction was validated using pull-down and immunoprecipitation assays. Moreover, ERBIN floated, in sucrose gradients, in the same membrane fractions as SARA and EEA1, known early endocytic markers, and overexpressed SARA recruited ERBIN to early endosomes. We cannot rule out that there is also a minor colocalisation at the plasma membrane, as SARA has been shown to interact with TGFb receptors at the plasma membrane (Di Guglielmo et al., 2003) and ERBIN is also detected at the plasma membrane (Borg et al., 2000) . Although the localisation of ERBIN on early endosomes has not been reported previously, individual ERBIN-positive cytosolic vesicles have been described, by immunohistochemistry, in basal cell carcinoma (BCC) (Lebeau et al., 2005) , and punctate ERBIN staining has been observed, by immunofluorescence, in proximal dendrites (Calin-Jageman et al., 2007) . Taken together, we define ERBIN as a newly identified SARA-interacting protein, which can colocalise with the latter on early endosomes.
We mapped the ERBIN interaction domain of SARA (Fig. 3) and concluded that it is contained within the region comprising amino acids 730-926, downstream of the SBD (Tsukazaki et al., 1998) and PP1BM (Bennett and Alphey, 2002 ), which we have called the ERBID. We additionally mapped the SARA interaction domain of ERBIN (Fig. 4) and found that a 25-amino-acid domain (amino acids 1241-1265) of ERBIN is responsible for the interaction with SARA. Because these 25 amino acids were included in a longer 110-amino-acid stretch (1172-1282) that has been shown to interact with SMAD2/3 (Warner et al., 2003; Dai et al., 2007) , we further defined the interaction domain of SMAD2 and SMAD3 on ERBIN. Much to our surprise, the SMAD2 and SARA-interacting domains of ERBIN were identical, being contained between amino acids 1241 and 1265. The interaction domain of ERBIN with SMAD3 was contained within a slightly larger area between amino acids 1208 and 1265. Additional electrostatic contacts between Arg279 of the MH2 domain of SMAD3 and Glu1321 of the PDZ domain of ERBIN might also participate in the SMAD3-ERBIN interaction, as suggested by recent molecular dynamics simulations (Deliot et al., 2009) . Because the area between amino acids 1208 and 1265 binds SARA, SMAD2 and SMAD3 we have called it the SSID.
The fact that the same short unstructured region of ERBIN (i.e. the SSID) can bind both SARA and SMAD2/3 is not so surprising in light of many recent studies that have revealed that the true functional state for many proteins and protein domains is intrinsically unstructured (Wright and Dyson, 1999; Uversky et al., 2005; Fink, 2005; Dyson and Wright, 2005; Tompa, 2002; Dunker and Obradovic, 2001; Dyson and Wright, 2002) . Protein regions or full-length proteins that are intrinsically disordered (IDPs) lack a single stable three-dimensional structure under physiological conditions, but adopt a well-defined conformation upon interacting with a target molecule in a manner different from that of the induced fit. Similar suggestions have been made in the past for the interactions of the SMAD2/3 MH2 domain, which is known to bind a diverse group of ligands that are completely unrelated in sequence and structure, ranging from transcription factors to receptors and membrane-anchoring proteins. X-ray, nuclear magnetic resonance (NMR), biophysical and bioinformatics studies have recently suggested that at least some of these interactions, including the one with SARA, are mediated by a number of hydrophobic patches distributed over the surface of MH2 that are able to recognise disordered regions of proteins in an extended conformation (Wu et al., 2000; Chong et al., 2004) . SARA, in particular, interacts with SMAD2/3 through its natively unstructured SBD, which makes extensive hydrophobic contacts with MH2 and folds upon binding. Thus, the data presented in this work render ERBIN as a new potential hub protein with its intrinsically disordered regions, such as the SSID, contributing to several of its multiple interactions, including those with SARA and SMAD2/3.
The present work adds an unexpected twist to the sequestration model in which ERBIN physically sequesters SMAD2/3-P and prevents it binding to SMAD4, thereby inhibiting their accumulation in the nucleus and blocking TGFb-dependent transcriptional activation (Dai et al., 2007) . Indeed, this work provides evidence that SARA plays a regulatory role in the SMAD2/3-ERBIN interaction. We have shown that SARA and SMAD2/3 bind to ERBIN independently of each other, thereby competing for binding to the SSID of ERBIN. This result suggests that the response of a cell to TGFb and activin A can be regulated by the relative concentrations of SMAD2/3, SARA and ERBIN, as well as the binding affinities, of these proteins. Indeed, a cell with a high ratio of ERBIN/SARA concentration is expected to sequester ligand-induced SMAD2/3-P, thereby inhibiting their nuclear accumulation and transcriptional effects, as shown previously (Dai et al., 2007) . By contrast, a cell with high ratio of SARA/ERBIN concentration is expected to compete the sequestering capacity of ERBIN; following SMAD2/3 phosphorylation, higher levels of SARA should be able to maximize the nuclear accumulation of SMAD2/3-P as SARA competes for their binding to the SSID of ERBIN (Fig. 7) . Indeed, overexpression of the ERBID peptide in HEK-293 cells not only increased the transcriptional response to TGFb, but also reversed the negative effect of the overexpression of ERBIN on TGFb-induced transcriptional activation of CAGA-luc. Likewise, overexpression of SARA also reversed the inhibition of TGFbinduced transcriptional activation of CAGA-luc imposed by the overexpression of ERBIN. This is depicted in the model in Fig. 8 . The colocalisation of SARA and ERBIN on early endosomes suggests that the above regulations take place, at least partly, in this cellular compartment.
Interestingly, in a very recent study, the abundance of ERBIN was found to be a key factor determining the differential outcome of TGFb signalling in epithelial cells compared with that in fibroblasts. Indeed, in epithelial cells that have a high abundance of ERBIN, the latter forms a heterodimer with MERLIN, which inhibits the phosphorylation of MERLIN upon TGFb-induced PAK2 activation, thereby allowing MERLIN to exert its tumour suppression activity. Fibroblasts have low levels of ERBIN and thus MERLIN does not exist in a heterodimer with ERBIN and hence MERLIN becomes a substrate for PAK2 phosphorylation and inactivation. Inactivation of the tumour suppression activity of MERLIN allows fibroblasts to proliferate upon TGFb administration (Wilkes et al., 2009 ). Thus, the abundance of ERBIN in cells determines the outcome of TGFb signalling by regulating the non-SMAD pathway downstream of PAK2. It appears that the level of ERBIN in cells also has a regulatory role in TGFb-induced SMAD2/3-dependent transcription, as illustrated in this study and by others (Dai et al., 2007) . Here, we additionally demonstrate that the regulatory role of ERBIN on SMAD2/3-dependent transcription is influenced by the level of SARA, being part of a more-complex interplay between the concentrations and binding affinities of SARA, SMAD2/3 and ERBIN. Interestingly, there are several phosphorylatable residues within the SSID and in its vicinity, as predicted by the DEPP Fig. 7 . The competition between SARA and ERBIN for binding to SMAD2/3 has functional consequences for TGFb signalling. (A) Overexpression of GST-SSID inhibits, whereas ERBIN (isoform 7) has no effect on, TGFb signalling. HEK-293 cells were transfected with CAGA-luc and GST-SSID, ERBIN (isoform 7) or ERBIN, and vector controls. Luciferase assays were performed as outlined in the Materials and Methods. The lysates were immunoblotted with antibodies against GST, ERBIN or Myc. (B) SARA 730-926 overexpression and ERBIN knockdown do not affect SMAD2/3 phosphorylation kinetics. HEK-293 cells were either transfected with GFP-SARA 730-926, GFP alone or siRNA targeting ERBIN, and were then serum starved and stimulated with TGFb. Phosphorylation of SMAD2/3 was detected by immunoblotting (IB) with antibodies specific for SMAD2-P (PS2) or PSMAD3-P (PS3). (C) SARA 730-926 overexpression affects complex formation between SMAD3 and SMAD4. HEK-293 cells were transfected with the indicated plasmids and cell lysates subjected to anti-FLAG immunoprecipitation (IP). Immunoprecipitates were immunoblotted with anti-Myc antibody to detect Myc-SMAD3 co-immunoprecipitated with FLAG-SMAD4, and anti-FLAG antibody to ensure equal immunoprecipitation of FLAG-SMAD4. Total lysates were immunoblotted with anti-GFP antibody to detect GFP and GFP-ERBID, anti-HA antibody to detect HA-ALK5ca, anti-FLAG antibody to detect FLAG-SMAD4 and antiMyc antibody to detect Myc-SMAD3 and Myc-ERBIN. SMAD3 and SMAD4 bands were quantified by densitometry and the SMAD3 coimmunoprecipitated by SMAD4 is shown in the graph, after normalisation against the intensity of the immunoprecipitated SMAD4 band. The ratio of SMAD3:SMAD4 band intensities in the control experiment was given the arbitrary value 1. The data are means¡s.e. for four independent experiments (a representative blot is shown). *P,0.05. (D) SARA 730-926 enhances and ERBIN overexpression inhibits nuclear accumulation of GFP-SMAD2 upon TGFb stimulation. HaCaT cells were transfected with GST, GST-SARA 730-926 or HA-ERBIN, and were then serum starved and stimulated with TGFb for 1 hour. Statistical analysis of cells transfected with GST-SARA 730-926 or GST alone with a ratio of fluorescence intensity (nucleus:cytoplasm) higher than 2.8. In the case of HA-ERBIN overexpression, GFP-SMAD2 accumulation in the nucleus or retention in the cytoplasm was estimated in .150 cells per experiment in three independent experiments. The graph represents the results from the three experiments. (E) siRNA against ERBIN or overexpression of SARA 730-926 enhances TGFb-induced expression of plasminogen activator inhibitor 1 (PAI-1). HEK-293 cells were transfected either with an siRNA against ERBIN or infected with adenoviruses expressing GFP alone, GFP-SARA 730-926 or GFP-SARA 730-773. Western blot analysis following siRNA transfection was performed using an anti-ERBIN polyclonal antibody. b-Actin is shown as a loading control. Anti-GFP antibody was used to detect viral infection. siRNA against ERBIN enhances TGFb induced expression of PAI by ,1.83-fold (*P,0.05 compared with control; n54) and overexpression of ERBID and SARA 730-773 enhances TGFb-induced expression of PAI-1 by ,2.6-and by ,2.4-fold, respectively (*P,0.05 compared with control; n53). 8 . A model illustrating the interactions between SARA, ERBIN and SMAD2/3. ERBIN interacts with SARA using a domain that interacts also with SMAD2 and SMAD3 (amino acids 1208-1265, SSID). As a consequence, SARA competes with SMAD2/3 for binding to ERBIN. As ERBIN binds and segregates phosphorylated SMAD2/3 in the cytoplasm, SARA not only ensures proper presentation of SMAD2/3 for phosphorylation by TGFb and activin A receptors but also facilitates the nuclear transfer of phosphorylated SMAD2/3 by competing for their cytoplasmic segregation by ERBIN. Thus, the cellular response to TGFb/activin A might be regulated by a complex interplay between the relative concentrations of SARA, ERBIN and SMAD2/3, as well as their binding affinities. See the Discussion for details.
algorithm (Iakoucheva et al., 2004) ; these have been also experimentally detected in a large-scale phosphoproteomic survey of tyrosine kinase activity using a large number of nonsmall cell lung cancer (NSCLC) cell lines and NSCLC tumours (Rikova et al., 2007) . Questions remaining include: does phosphorylation within the SSID in some way regulate the affinity of SARA and/or SMAD3 binding? How is the effect of ERBIN on non-SMAD and SMAD-dependent responses integrated in the overall response of a cell to TGFb? Are the effects of ERBIN on ERBB2 localisation and inhibition of ERK1/2 phosphorylation functionally linked with those of TGFb signalling in the cells? Definitely, more work is required to elucidate these issues.
In conclusion, we have identified ERBIN as a novel SARAinteracting protein that can be recruited by the latter to early endosomes, where SARA predominantly resides. SARA binds to ERBIN using a new domain downstream of the SBD and PP1BM, which we have called the ERBID. ERBIN interacts with SARA using a domain that interacts also with SMAD2 and SMAD3 which we called the SSID (amino acids 1208-1265). As a consequence, SARA competes with SMAD2/3 for binding to ERBIN. Because ERBIN binds and segregates phosphorylated SMAD2/3 in the cytoplasm, thereby inhibiting SMAD2/3-dependent transcription, overexpression of SARA or the ERBID peptide reverses the inhibitory effect of ERBIN on SMAD2/3-dependent transcription. Thus, SARA not only ensures proper presentation of SMAD2/3 for phosphorylation by TGFb and activin A receptors but also facilitates the nuclear transfer of phosphorylated SMAD2/3 by competing for their cytoplasmic segregation by ERBIN. Our data suggest that the response of cells to TGFb and activin A might be regulated by a complex interplay between the relative concentrations of SARA, ERBIN and SMAD2/3, as well as their binding affinities.
Materials and Methods
Identification of SARA interacting proteins by Y2H screening
Yeast two-hybrid (Y2H) screening and data analysis were performed by Hybrigenics (Paris, France). SARA (amino acids 665-1323) was cloned into a Y2H vector optimized by Hybrigenics. A random primed human placental cDNA library was used for the screen.
Expression plasmids and siRNAs
PAI expression
HaCaT cells were transfected with an siRNA targeting ERBIN or scrambled siRNA (20 nM final concentration) using RNAiMAX (Invitrogen) or infected with adenoviruses expressing GFP-SARA 730-926, GFP-SARA 730-773 or GFP alone. At 48 hours after transfection cells were starved of serum (0.2% FSC) overnight and then induced with 5 ng/ml TGFb1 for 10 hours. Cell lysates were subjected to SDS-PAGE analysis, followed by western blot analysis using an antibody against PAI-1.
Antibodies and recombinant proteins
Recombinant TGFb1 was purchased from Peprotech. Recombinant activin A was a gift from Yuzuru Etoh (Ajinomoto, Japan) and Marko Hyvonen (Department of Biochemistry, University of Cambridge, Cambridge, UK) (Harrington et al., 2006) . BMP-2 was from Immunotools. An anti-EEA1 rabbit polyclonal antibody was kindly provided by Marino Zerial (MPI-CBG, Dresden, Germany). A mouse monoclonal anti-EEA1 antibody was purchased from Transduction Laboratories. Anti-FLAG M2 antibody was purchased from Sigma-Aldrich. Rat monoclonal anti-HA antibody was from Roche. The 9E10 (against Myc) monoclonal antibody was purified from the hybridoma using standard techniques. Goat and rabbit polyclonal antibodies recognising SARA, SMAD4, PAI and SMAD2/3 were purchased from Santa Cruz Biotechnology. Mouse monoclonal anti-GFP antibody was purchased from Roche. Anti-actin and anti-CD39 antibodies were purchased from Chemicon, and anti-b-tubulin antibody from the Developmental Studies Hybridoma Bank (DSHB, University of Iowa, Iowa City, IA). Anti-PSMAD2 and anti-PSMAD3 antibodies were purchased from Millipore and Rockland, respectively.
Indirect immunofluorescence
NIH 3T3 cells were transfected with Effectene (Qiagen). Indirect immunofluorescence, confocal microscopy and image acquisition were carried out as described previously .
GST pull-down assays GST fusion proteins or GST alone (,15-30 mg, equimolar amounts) were incubated for 1 hour at 4˚C with 20 ml of glutathione-agarose beads (Amersham Biosciences), in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% NP-40 and protease inhibitors from Roche). After washing three times with assay buffer, the beads were combined with HEK-293 cell extracts transiently transfected or infected with the protein of interest and incubated for a further 4 hours at 4˚C with rotation. The beads were washed five times before eluting the bound proteins with SDS sample buffer.
Immunoprecipitation and immunoblotting
HEK-293 cells were transfected for 36 hours using FuGENE 6 (Roche) and lysed in buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100 and protease inhibitors from Roche). The lysates were pre-absorbed with protein G beads and incubated with the appropriate antibodies for 12-18 hours at 4˚C with rotation. Protein G beads were added for 4 hours at 4˚C, with rotation, followed by five washes with lysis buffer. Immunoprecipitates were separated by SDS-PAGE and immunoblotted. The lysis buffer for complex formation contained 1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 10% glycerol, 1 mM sodium vanadate, 25 mM sodium fluoride, 50 nM okadaic acid and 10 mM 2-glycerophosphate and protease inhibitors.
Reporter assays for SMAD-dependent transcription HEK-293 cells were transfected using FuGENE 6 in full medium, 20 hours later the cells were placed into reduced serum medium (0.2% FBS) for 8 hours. Then, cells were treated or not with 50 ng/ml activin A, 2.5 ng/ml TGFb1 or 100 ng/ml BMP2 and incubated for an additional 16 hours. Cells were processed for luciferase as described in the Promega E4030 luciferase kit, and b-galactosidase (b-gal) activity was measured using a standard protocol. Relative light units were measured using a Berthold luminometer and standardized for transfection efficiency using the b-gal values. Cells were plated in triplicate wells and assays were repeated three times.
siRNAs assays in stable cell lines
For the generation of stable transfectants, A431 cells were co-transfected with CAGA-luc and pRSV puromycin plasmids using FuGENE 6. After 24 hours, cells were subcultured into medium containing 0.4 mg/ml puromycin. Two clones highly responsive to TGFb1 and activin A were selected for re-transfection with Renilla pRL-TK vector plus a neomycin resistance cassette, and isolated clones were selected in the presence of 0.75 mg/ml G418 and 0.4 mg/ml puromycin and tested for CAGA-luc activation by activin A and TGFb1 and constitutive expression of Renilla luciferase. A total of two clones were selected and were used for the studies. The Dual luciferase kit was used according to the manufacturer's instructions (Promega).
Preparation of ERBIN polyclonal antiserum
A rabbit polyclonal antibody was generated using as antigen GST-ERBIN 1240-1371 protein. Crude serum was first depleted of anti-GST antibodies, then incubated with GST-ERBIN to affinity purify anti-ERBIN antibodies. Antibody specificity was tested on the endogenous and overexpressed ERBIN, the ERBIN siRNA-depleted lysate and by competition with recombinant protein.
Sequence analysis
The internet server PredictProtein was used for secondary structure predictions (Rost et al., 2004) . Disorder predictions were carried out using the network programs PONDR-VXLT (Romero et al., 2001; Romero et al., 1997) , RONN (Yang et al., 2005) , DisEMBL (Linding et al., 2003) , IUPred (Dosztanyi et al., 2005a; Dosztanyi et al., 2005b) and DISOPRED2 (Ward et al., 2004) . The above programs predict probable disordered regions of proteins on the basis of their primary sequence.
Competition experiment
HEK-293 cells were infected for 24 hours with FLAG-tagged SARAD1-664 adenovirus or transiently transfected with myc-SMAD2ca or myc-SMAD3ca for 36 hours using FuGENE 6 (Roche). Both were lysed with lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% NP-40) containing protease inhibitors. Briefly, E3C GST fusion protein or GST alone (,5-10 mg, equimolar amounts) were incubated for 2 hours at 4˚C with 20 ml of glutathione-agarose beads, in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1% NP-40). After washing three times with assay buffer, the beads were combined with HEK-293 cell extracts transiently transfected with Myc-SMAD2ca or Myc-SMAD3ca and rotated for 4 hours at 4˚C. Finally, the beads were washed once with assay buffer before adding HEK-293 cell extracts infected with FLAG-SARAD1-664 adenovirus and further incubated overnight at 4˚C. Bound proteins were subjected to SDS-PAGE (12% gels) and analysed by western blotting.
Cytoplasmic and nuclear SMAD2 accumulation
HaCaT cells stably expressing GFP-SMAD2 were transfected with either GST alone, GST-SARA 730-926 or HA-ERBIN. Cells were stimulated with 1 ng TGFb (this concentration was submaximal and allowed us to see also some cytoplasmic GFP-SMAD2) and after 1 hour, cells were fixed and incubated with either anti-GST or anti-HA antibodies and appropriate secondary antibodies. Images were taken using a Leica TCS-SP scanning confocal microscope using non-saturating conditions. Relative intensities of cytoplasmic and nuclear signals of GFP-SMAD2 were estimated in all transfected cells using ImageJ. To compare the nuclear accumulation of GFP-SMAD2 between the control (GST) and the GST-ERBID-expressing HaCaT cells, we evaluated the percentage of transfected cells in which the nuclear:cytoplasmic ratio was greater than 2.8 and used an unpaired Student's t-test to statistically compare the means of three independent cell groups. The rather high nuclear:cytoplasmic ratio of 2.8 was selected because in the stably transfected HaCaT cell line some cells inevitably express high levels of GFP-SMAD2, which might influence the background level of the cytoplasmic fluorescence.
Statistical analysis
Two-sided Student's t-tests and a significance criterion of P,0.05 were used. Three groups were compared using the one-way ANOVA and significance criterion of P,0.05. Statistical analysis was performed with the Statistical Package for the Social Sciences 10.0 statistical software (SPSS).
